An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.
The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.
Dasiglucagon has potential as a fast, effective treatment for severe hypoglycemia in patients with type 1 diabetes, show phase III study data presented at the 79th ADA Scientific Sessions in San Francisco, California, USA.
The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.
The novel, orally active vascular adhesion protein-1 inhibitor ASP8232 effectively reduces albuminuria, with few side effects, in patients with type 2 diabetes and chronic kidney disease, phase II study data show.
Modestly increasing glucagon levels when commencing physical activity could be an effective strategy for preventing exercise-induced hypoglycemia among patients with type 1 diabetes, results of a randomized crossover trial suggest.
Intensive blood pressure management benefits patients whether or not they have diabetes and regardless of their baseline level of cardiovascular disease risk, shows a pooled analysis of the SPRINT and ACCORD-BP trials.
Finding from the PROCEED trial show that dietary salt restriction helps to reduce albuminuria in patients with type 2 diabetes taking losartan, the investigators report in The Lancet Diabetes & Endocrinology.
Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.
An analysis in JAMA shows that the price of PCSK9 inhibitors, recently shown to be effective against diabetic dyslipidemia, will need to fall by nearly three-quarters before they can be considered cost-effective even in high-risk patients with established cardiovascular disease.